Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Releases Quarterly Earnings Results, Hits Expectations

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) released its quarterly earnings data on Thursday. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03), FiscalAI reports. The company had revenue of $1.43 million for the quarter, compared to the consensus estimate of $2.32 million. Lineage Cell Therapeutics had a negative return on equity of 73.06% and a negative net margin of 246.58%.

Here are the key takeaways from Lineage Cell Therapeutics’ conference call:

• Lineage acquired NeuroAirmid and its clinical-stage Huntington’s disease cell therapy, HUNT1, adding a third clinical-stage asset. Six patients have been dosed with no serious adverse events reported, but the ongoing study is early and primarily designed to assess safety.
• Management said the deal’s near-term costs are manageable: initial external cash payments were about $4.3 million, and the company expects its cash runway to extend into Q2 2028, one quarter earlier than previously forecast. Most remaining payments are contingent on clinical progress and can be paid partly in stock.
• Lineage reported progress with its 5D manufacturing platform, including successful production of islet-cell precursors in a 3D system and scale-up to three liters; a related patent is expected to expire in 2043. The company expects to share initial COR1 preclinical data in Q1 2027.
• For OpRegen, Lineage confirmed that clinical material from multiple batches was produced and shipped to Genentech, but said it cannot provide guidance on its partner’s development timeline. OPC1’s DOSED study continues, with a third patient surgery planned before year-end and a fourth patient expected in Q1.
• Third-quarter revenue fell to about $1.5 million from $3.7 million a year earlier, while operating expenses rose to $8.8 million from $7.5 million. Reported net income of $4.2 million was driven primarily by a non-cash warrant-liability remeasurement, rather than improved operating results.

Lineage Cell Therapeutics Stock Down 10.8%

Lineage Cell Therapeutics stock traded down $0.12 during trading hours on Thursday, hitting $0.99. The stock had a trading volume of 1,375,185 shares, compared to its average volume of 1,288,077. The stock has a market cap of $250.46 million, a price-to-earnings ratio of -5.21 and a beta of 1.68. Lineage Cell Therapeutics has a one year low of $0.88 and a one year high of $1.99. The business’s 50 day simple moving average is $1.00 and its 200-day simple moving average is $1.30.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a biotechnology company developing cell-based therapies for serious medical conditions. The company uses its cell therapy platform to create and manufacture specialized human cells intended to replace or support damaged cells and tissues. Its programs include OpRegen, a retinal pigment epithelial cell therapy being developed for retinal diseases; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ANP1, an auditory neuron progenitor cell program for hearing loss; and VAC2, a cell-based cancer immunotherapy.